Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 35

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 35
---
 a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them from sharing such trade secrets or from using that technology or information to compete with us.
If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.

 20 

Risks Related
to Our Employee Matters, Managing Growth and Macroeconomic Conditions 

If we successfully identify new product candidates
and license those rights, then our future success will also depend on our ability to attract, hire, retain and motivate executives, key
employees, and our general workforce. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then we will be highly dependent on the product development, clinical and business development expertise
of the principal members of our management, scientific and clinical teams. If we are unable to raise more capital in the near term, we
may be required to cease our operations altogether.

Moreover, our business plan relies significantly on
the continued services of our President and Chief Executive Officer, Steven King. If we were to lose his services, including through death
or disability, our ability to continue to execute our business plan would be materially impaired. We do not maintain “key person”
insurance for any of our executives or other employees. The Company has not entered into an employment agreement with Mr. King, or any
other officer of the Company.

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then recruiting and retaining qualified scientific, clinical, regulatory, and manufacturing personnel
is critical to our success. We also may experience competition for the hiring of scientific and clinical personnel from universities and
research institutions. In addition, we have historically relied on consultants and advisors, including scientific and clinical advisors,
to assist us in product manufacturing, preclinical development, clinical development, regulatory strategy, and commercial strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with
other entities that may limit their availability to provide services to us. If we are unable to attract and retain high quality personnel,
our ability to pursue our development strategy will be limited.

If we successfully identify